Representatives from the U.S. Army Medical Materiel Development Activity (USAMMDA) joined thousands of biotechnology industry experts this week in San Diego for the Biotechnology Innovation Organization’s annual convention, BIO 2024.
USAMMDA is responsible for developing and delivering critical products designed to protect and preserve the lives of servicemembers. These products include drugs, vaccines, biologics; infectious disease, TBI, and PTSD diagnostics; and medical support equipment intended to maximize survival in austere or combat conditions.
Based at Fort Detrick, Maryland, under the U.S. Army Medical Research and Development Command (USAMRDC), USAMMDA works with medical experts and stakeholders from the Army, Navy, Air Force, Marines, and Special Forces, as well as the U.S. Food and Drug Administration (FDA) and private sector partners, to develop and deliver medical solutions to Warfighters across the globe.
BIO 2024, which draws over 15,000 industry leaders and experts in biological sciences, offers the USAMMDA team unparalleled access to the biotechnology organizations that can help advance the DOD’s development missions, according to Judy Holian, branch chief of USAMMDA’s Office of Research and Technology Applications.
USAMMDA currently has more than two dozen ongoing research and development efforts across the spectrum of combat casualty care. For more information about the organization and how to partner with the U.S. Army medical development enterprise, visit the USAMMDA website.
Story adapted from T. T. Parish, USAMMDA